Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bauer, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bauer, K. A.
(Chest. 2003;124:364S-370S.)
© 2003 American College of Chest Physicians

New Pentasaccharides for Prophylaxis of Deep Vein Thrombosis*

Pharmacology

Kenneth A. Bauer, MD

* From the Department of Medicine, Harvard Medical School, Hematology Section, VA Boston Healthcare System, and Beth Israel Deaconess Medical Center, Boston, MA.

Correspondence to: Kenneth A. Bauer, MD, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215; e-mail: kbauer{at}bidmc.harvard.edu

Fondaparinux is the first of a new class of antithrombotic compounds, the synthetic pentasaccharides. By binding rapidly and strongly to antithrombin, its sole physiologic target in plasma, fondaparinux catalyzes specifically the inhibition of factor Xa, which results in effective and linear dose-dependent inhibition of thrombin generation. Fondaparinux does not bind to platelets. Its antithrombotic effect has been demonstrated in several animal models of arterial and venous thrombosis. At equivalent antithrombotic concentrations, fondaparinux induced less bleeding than unfractionated heparin in experimental bleeding models. Furthermore, it did not cross-react with sera from patients with heparin-induced thrombocytopenia. Administered subcutaneously, the absorption of fondaparinux is complete, rapid, and independent of dose. It has a linear pharmacokinetic profile, and its half-life of approximately 17 h allows for once-daily dosing. Fondaparinux is almost completely excreted by the kidneys. Owing to the limited intrasubject and intersubject variability, routine monitoring and dose adjustments should not be required for most patients. Fondaparinux has been approved for use in thromboprophylaxis after major orthopedic surgery, where it has demonstrated its efficacy compared to a low-molecular-weight heparin. Its clinical development in other indications is ongoing.

Key Words: fondaparinux • idraparinux • low-molecular-weight heparin • pentasaccharide • pharmacokinetics • thromboprophylaxis • venous thromboembolism




This article has been cited by other articles:


Home page
 Am J Crit CareHome page
L. G. Futterman and L. Lemberg
A Silent Killer--Often Preventable
Am. J. Crit. Care., September 1, 2004; 13(5): 431 - 436.
[Full Text] [PDF]

Home page
 CirculationHome page
J. I. Weitz
New Anticoagulants for Treatment of Venous Thromboembolism
Circulation, August 31, 2004; 110(9_suppl_1): I-19 - I-26.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. I. Weitz, S. Middeldorp, W. Geerts, and J. A. Heit
Thrombophilia and New Anticoagulant Drugs
Hematology, January 1, 2004; 2004(1): 424 - 438.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Chest Physicians.